Sahajanand Medical Technologies IPO Analysis & Review

Quick Answers

What is the Sahajanand Medical Technologies IPO GMP today? The Sahajanand Medical Technologies IPO GMP is ₹30 as of 13/10/2026, 5:20:22 am. The IPO price band is ₹327 - ₹344. GMP represents an unofficial grey-market indication and does not guarantee the listing price.

When does Sahajanand Medical Technologies IPO open? The Sahajanand Medical Technologies IPO opens on 2026-10-15 and closes on 2026-10-19.

What is the Sahajanand Medical Technologies IPO subscription status? The overall subscription is 0x.

Key IPO Information

ViewIPO AI Analysis Score

The Sahajanand Medical Technologies IPO scored 58/100 (High Risk) in our deep analysis.

Frequently Asked Questions

What is the primary business of Sahajanand Medical Technologies?

Sahajanand Medical Technologies develops, manufactures, and sells medical devices used in vascular and structural heart interventions, including coronary stents, balloon catheters, TAVI devices, and occluders.

In how many countries does the company market its products?

The company markets its products in 77 countries, including India, Europe, and other international markets.

What was the company's revenue growth rate from FY24 to FY26?

Revenue grew from ₹902 crore in FY24 to ₹1,211 crore in FY26, representing a CAGR of approximately 15.8% over the two-year period.

What percentage of the company's purchases are imported?

Imports accounted for up to 77.18% of total purchases in FY26, indicating high dependence on imported raw materials and components.

Is the IPO a fresh issue or an offer-for-sale?

The IPO is structured as an offer-for-sale (OFS); the company will not receive any proceeds, and the net proceeds will go to the promoter selling shareholders.

What are the key manufacturing locations and certifications of the company?

The company operates three manufacturing facilities—two in India (Surat and Hyderabad) and one in Thailand—all holding ISO 13485:2016 certification for medical device quality management systems.

What is the size of the company's patent portfolio as of the RHP date?

As of the RHP date, Sahajanand Medical Technologies had 119 granted patents globally and 78 pending patent applications, along with five design registrations in India.

View IPO
View IPO
Home›India›Sahajanand Medical Technologies ()
Sahajanand Medical Technologies Logo

Sahajanand Medical TechnologiesNSE / BSE:

Analyzed by ViewIPO Financial Research Team
Medical DevicesIndiaFiled 2026-10-15Listing 2026-10-23Size ₹475.59Cr
Lot Size 43
Live GMP
₹30 (+10.17%)
Check Allotment
Status Link

Is Sahajanand Medical Technologies IPO Good? Quick Verdict

Sahajanand Medical Technologies IPO scored 58/100 (High Risk) in our deep analysis. The strongest pillar is Governance at 65/100, while Valuation is the primary concern at 50/100. Sahajanand Medical Technologies demonstrates strong international growth and a robust R&D pipeline, but faces profitability challenges and supply chain dependencies that warrant caution.

IPO Score
58/100
High Risk

Quick Verdict

Strong international revenue growth with 23.34% CAGR (FY24-FY26)
Market leadership with ~25% share of India's drug-eluting stents market
Extensive R&D pipeline with 119 granted patents and 78 pending applications
Consolidated net loss of ₹7.35 crore in FY24 and standalone losses in FY24 and FY25
High dependence on imported raw materials, accounting for up to 77% of purchases
Customer and supplier concentration risks, with top 10 suppliers representing ~59% of purchases

Company Snapshot

Revenue (TTM)
₹1211Cr↑ 18.15% YoY
Profitability
—Pending Data
Gross Margin
— 
Market Cap
—Pending Data
IPO Size
₹475.59Cr 
Industry
Medical Devices 
P/E Ratio
—Pending Data

Risk Breakdown

Governance
65
Moderate
Financial
60
Moderate
Valuation
50
Expensive
Competition
55
Expensive
Dilution
60
Moderate
Promoter / Mgmt
60
Moderate

AI Summary

Sahajanand Medical Technologies Ltd is a developer and manufacturer of medical devices for vascular and structural heart interventions, with a presence in 77 countries and three manufacturing facilities in India and Thailand. The company reported revenue growth from ₹902 crore in FY24 to ₹1,211 crore in FY26, driven by a 23.34% CAGR in international sales. Despite its market leadership in drug-eluting stents and extensive patent portfolio, the company has incurred net losses in recent years and relies heavily on imported raw materials and a limited supplier base. The IPO is structured as an offer-for-sale, meaning the company will not receive any proceeds, and listing is expected to enhance visibility and provide liquidity to existing shareholders.

Overall Verdict: Sahajanand Medical Technologies demonstrates strong international growth and a robust R&D pipeline, but faces profitability challenges and supply chain dependencies that warrant caution.

Key Highlights

  • •Revenue from operations grew from ₹902 crore in FY24 to ₹1,211 crore in FY26.
  • •International sales contributed 73.87% of revenue in FY26, up from 65.20% in FY24.
  • •Holds approximately 25% of India's drug-eluting stents market by sales volume.
  • •Operates three ISO 13485:2016 certified manufacturing facilities in Surat, Hyderabad, and Thailand.
  • •Possesses 119 granted patents globally and 78 pending patent applications as of RHP date.
  • •Revenue from vascular intervention devices accounted for 61.14% of FY26 sales.
  • •The IPO is an offer-for-sale; the company will not receive any proceeds.

Financial Performance

Revenue (Annual)

↑ +18.1% YoY

INR in Crores

Net Income (Annual)

↑ +100.0% YoY

INR in Crores

EBITDA vs PAT

EBITDA YoY

INR in Crores

EBITDA
PAT

IPO Timeline

IPO Opens2026-10-15
IPO Closes2026-10-19
Basis of Allotment2026-10-21
Refunds & Demat2026-10-21
Listing Date2026-10-23

Valuation Analysis

IPO Price₹327 - ₹344
Estimated Fair Value
Pending Data
Valuation Premium
Pending
vs Fair Value

IPO DNA

Growth
58
Governance
65
Profitability
60
Valuation
50
Competition
55
Execution
60

Pros vs Cons

Pros

  • Strong international revenue growth with 23.34% CAGR (FY24-FY26)
  • Market leadership with ~25% share of India's drug-eluting stents market
  • Extensive R&D pipeline: 119 granted patents and 78 pending applications
  • Diversified geographic presence across 77 countries
  • ISO 13485:2016 certified manufacturing facilities in India and Thailand

Cons

  • Consolidated net loss of ₹7.35 crore in FY24 and standalone losses in FY24 and FY25
  • High dependence on imported raw materials (up to 77% of purchases)
  • Supplier concentration: top 10 suppliers account for ~59% of purchases
  • Limited long-term agreements with distributors and suppliers
  • Regulatory challenges in certain international markets affecting product approvals

Financial Health

Revenue Growth
15.8% CAGR (FY24-FY26) (Good)
Debt Level
Working capital loans of ₹240.99 crore as of June 2026 (Moderate)

Institutional Signals

Anchor Investors
Undisclosed
VC Backing Tier
Undisclosed
Strategic Partners
Undisclosed

Sahajanand Medical Technologies IPO Reddit Pulse & Sentiment

Real-time Reddit discussions & retail sentiment

No Public Data Available

We couldn't find any significant public discussions or retail sentiment threads for this IPO at the moment.

Disclaimer: These are raw community discussions aggregated from public forums. The AI summary and Reddit comments do not constitute financial advice. Always conduct your own independent research.

Sahajanand Medical Technologies IPO — Frequently Asked Questions

Related IPO Reports

Zetwerk

Zetwerk

ZETWERK
55/100
View Report
Tonbo Imaging

Tonbo Imaging

TONBO
55/100
View Report
Fusion CX

Fusion CX

FUSIONCX
55/100
View Report
Ravita Engineering Services

Ravita Engineering Services

RAVITA
55/100
View Report
HD Fire Protect

HD Fire Protect

HDFIRE
59/100
View Report
View All Active & Upcoming IPOs View IPO Calendar

IPO Terminology Explained

Confused by terms like GMP, Kostak, or Subject to Sauda? Read our detailed guides in the IPO Glossary to understand the terminology before you invest.

Grey Market Premium (GMP)Subject to SaudaASBAOffer for Sale (OFS)
View Full Glossary

Source Citation: All financial data and risk metrics are derived from the official prospectus filed with the regulator (SEBI DRHP/RHP). ViewIPO algorithms process this public data for informational purposes. Not financial advice.

Want to analyze another IPO?

Search any stock, IPO, company, ticker or filing and get instant AI-powered analysis.

Frequently Asked Questions about Sahajanand Medical Technologies

What is the expected listing price of Sahajanand Medical Technologies?

The expected listing price depends on the live Grey Market Premium. Check the live GMP and expected listing price for Sahajanand Medical Technologies on our Live GMP Tracker.